BG Medicine (BGMD) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
Ladenburg Thalmann Downgrades BG Medicine (BGMD) to Neutral
November 13, 2014 11:22 AM ESTLadenburg Thalmann downgraded BG Medicine (NASDAQ: BGMD) from Buy to Neutral.
For an analyst ratings summary and ratings history on BG Medicine click here. For more ratings news on BG Medicine click here.
Shares of BG Medicine closed at $0.47 yesterday.
... More


